BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioCryst projects $1B peak sales for ORLADEYO, eyes global expansion

BioCryst Pharmaceuticals showcased strong performance driven by ORLADEYO's success, with a clear path towards $1 billion in peak sales and global expansion.
While facing challenges such as delays in BCX10013's development and managing expenses, the company remains focused on maximizing product value and market opportunities.
Opportunities lie in expanding ORLADEYO's market presence, exploring international sales, and investing in R&D for future growth and innovation.

BioCryst projects strong revenue growth for ORLADEYO, faces regulatory hurdles

BioCryst Pharmaceuticals demonstrates strong performance and revenue growth potential for ORLADEYO, aiming to exceed $320 million guidance for the year.
Challenges include revenue impact from free drug complexities and regulatory delays, with opportunities in global market expansion and pediatric therapy development.
The company's focus on patient care, financial stability, and long-term sales outlook positions BioCryst for continued growth and success in the pharmaceutical market.

BioCryst Pharmaceuticals on track to hit $320M in ORLADEYO sales

BioCryst Pharmaceuticals is confident in reaching $320 million in ORLADEYO sales this year through patient growth. Q3 and Q4 revenue growth expected to be steady, with opportunities for expansion outside the U.S.

BioCryst's ORLADEYO excels in Q3, faces challenges and growth opportunities

BioCryst Pharmaceuticals continues to see strong performance with ORLADEYO revenue and patient growth.
The company faces challenges with co-payment assistance programs and competitive market dynamics.
Opportunities lie in market education, pediatric patient expansion, and maintaining a competitive edge.
Despite expected expense increases, BioCryst remains focused on value creation and long-term growth.

BioCryst reports robust earnings, eyes $1B peak revenue for ORLADEYO

BioCryst Pharmaceuticals showcased strong financial performance and positive long-term data for ORLADEYO, aiming for $1 billion in global peak revenue.
While facing challenges with patient retention and market access, the company emphasized its growing product portfolio and accelerated path to profitability.
Opportunities lie in achieving profitability by 2026, improving market access, and leveraging therapy efficacy to drive revenue growth and market expansion.

BioCryst Pharmaceuticals excels in Q1, eyes Japanese market expansion

BioCryst Pharmaceuticals delivered strong Q1 results driven by ORLADEYO sales, raising revenue guidance for 2024 and advancing pipeline programs.
While facing challenges in expenses and gross to net margins, the company's strategic focus on market expansion and pipeline development presents growth opportunities.
Overall, BioCryst Pharmaceuticals shows promise with a balanced patient mix, strong market research projections, and high strategic interest in its flagship product.

BioCryst's ORLADEYO excels, revenue guidance raised amidst operational achievements

BioCryst Pharmaceuticals showcased robust performance in Q2 driven by ORLADEYO, with strong revenue growth and operational achievements.
Despite challenges like product portfolio diversification and profitability targets, the company's strategic focus on ORLADEYO's market expansion and revenue guidance increase highlights growth potential.
Opportunities lie in further leveraging ORLADEYO's success, exploring new market segments, and enhancing market strategies to drive sustained growth and market leadership.

BioCryst Pharmaceuticals reports robust revenue growth and pipeline advancements

BioCryst Pharmaceuticals delivered strong financial results driven by ORLADEYO's performance, showcasing market acceptance and revenue growth.
The company's pipeline advancements and proactive management approach position them well for future growth and product portfolio expansion.
While facing challenges in sustaining momentum and managing competition, BioCryst Pharmaceuticals has opportunities to capitalize on market demand and optimize operational strategies for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

In less than several weeks, BioCryst Pharmaceuticals (NASDAQ: BCRX) shares have advanced from $7.2 above $12, and the current price stands around $10.2. According to the latest news, the FDA approved Rapivab (peramivir injection), which is positive news for BioCryst Pharmaceuticals shareholders.

Is it the right moment for investing in BioCryst Pharmaceuticals shares?

Ocugen, Inc.

Voyager Therapeutics

Voyager Therapeutics (NASDAQ: VYGR) shares are trading lower Wednesday after the company announced that the FDA had notified Neurocrine that it placed a clinical hold on the RESTORE-1 clinical trials of the NBIb1-817. Voyager planned to support Neurocrine by sponsoring its trial.

Why BioCryst, Ocugen And Voyager Therapeutics Are Moving Today

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares jump after the FDA approved supplemental marketing application seeking approval for RAPIVAB (peramivir injection) to treat acute uncomplicated influenza to include patients six months and older who have been symptomatic for no more than two days.

BioCryst Gains After FDA Nod For Expanded Use of RAPIVAB

RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application for RAPIVAB ® (peramivir injection) expanding the patient population of RAPIVAB for the treatment of acute uncomplicated influenza to include patients six months and older who have been symptomatic for no more than two days. Prior to this approval, RAPIVAB had been indicated for patients two years and older.

BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares, which had been locked in a trading range since the start of January, broke out of the range Monday and rallied strongly, only to pull back in the next session. Monday's 39% Rally: BioCryst shares gap opened Monday's session about 26% higher and peaked at $12.04 in afternoon trading, representing a gain of 41.3%.

BioCryst Shares Slide As Reddit-Induced Rally Peters Out

BioCryst Pharmaceuticals surged 39% to a five-year high on Monday as Reddit investors declared a "BioWar" against short-sellers betting against the stock. The move followed a post on the r/WallStreetBets subreddit that called the company "the most undervalued stock in the market."  The post zeroed in on a new drug known as Orladeyo, a once-daily pill approved by the U.S. Food and Drug Administration in December 2020 meant to prevent attacks of hereditary angioedema (HAE). HAE is a genetically rare problem with the immune system that causes swelling and abdominal cramping.

BioCryst surges 30% to a 5-year high as Redditors declare 'BioWar' against short-sellers

Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

Implied Volatility Surging for BioCryst (BCRX) Stock Options

BioCryst (BCRX) gets approval in Japan for oral, once-daily Orladeyo 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years or older.

BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo

Fluidigm

Seelos Therapeutics

Adamis Pharmaceuticals

Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science tools focused on the analysis of single cells and industrial applications of genomics.

Why Fluidigm, Seelos Therapeutics And More Are Moving Today

The stock price of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is trading higher than 5% pre-market. This is why it happened.

BCRX Stock Price Increases Over 5% Pre-Market Today: Why It Happened

RESEARCH TRIANGLE PARK, N.C., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for oral, once-daily ORLADEYO™ (berotralstat) 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m. ET.

BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference

BioCryst (BCRX) will discontinue the study on its pipeline candidate, galidesivir, for treating patients with the novel coronavirus disease (COVID-19).

BioCryst (BCRX) Provides Updates on Galidesivir, Shares Fall

CryoPort

Both stocks are in the early stage of a long-term growth trajectory.

2 Ultra-High-Growth Healthcare Stocks That Are Just Getting Started

Teladoc

VistaGen Therapeutics

VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after Maxim raised its price target on the stock from $3 to $5. VistaGen Therapeutics is a biotechnology firm.

Why BioCryst, VistaGen And Teladoc Are Moving Today

RESEARCH TRIANGLE PARK, N.C., Dec. 22, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. The trial was not designed or sized to demonstrate clinical efficacy and no clinical efficacy benefit with galidesivir treatment compared to placebo treatment was observed in the trial.

BioCryst Provides Update on Galidesivir Program

RESEARCH TRIANGLE PARK, N.C., Dec. 21, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that in a Phase 1 clinical trial with BCX9250, an oral activin receptor-like kinase-2 (ALK-2) inhibitor discovered and developed by BioCryst for the treatment of fibrodysplasia ossificans progressiva (FOP), BCX9250 was safe and well tolerated at all doses studied, with linear and dose-proportional exposure supporting once-daily dosing.

BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva

Halozyme Therapeutics

QuidelOrtho Corp

Acceleron Pharma

The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U.S. population has spurred demand for healthcare products and services. The sector continues to undertake several technological advancements for boosting the digital space.

5 Healthcare Stocks That Fared Well in 2020 Amid the Pandemic

—Direct to patient shipments of the first oral, once-daily prophylactic treatment underway through Optime Care —  

BioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary Angioedema

RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m. ET.

BioCryst to Present at JMP Securities Hematology Summit

BioCryst received FDA approval for Orladeyo last week. The company quickly moved to raise cash and remove the financing overhang.

BioCryst Pharmaceuticals: Orladeyo Approved, Financing Overhang Removed

BioCryst (BCRX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

BioCryst (BCRX) in Focus: Stock Moves 6.1% Higher

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has received a price target increase from $13 to $14 by H.C. Wainwright.

BioCryst Stock Price: $14 Target By HC Wainwright

The recent FDA approval of Orladeyo (Berotralstat) has completely de-risked BioCryst's future. Orladeyo has the ability to be a "blockbuster drug" and we are of the opinion that it very much has the ability to become Standard of Care.

BioCryst: Time To Switch Hats? A Mid Cap Fits Now, Maybe A Large Cap?

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), Royalty Pharma plc (Nasdaq: RPRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the launch of ORLADEYO™ (berotralstat) in hereditary angioedema (HAE) and the development of its oral Factor D inhibitor, BCX9930.

News for BioCryst Pharmaceuticals Stock (BCRX)